key: cord-0758801-cx0ru57f authors: Ghadiri, Fereshteh; Sahraian, Mohammad Ali; Shayegannejad, Vahid; Ashtari, Fereshteh; Ghalyanchi, Hamidreza; Baghbanian, Seyed Mohammad; Mojdehipanah, Hossein; Majdi-Nasab, Nastaran; Hosseini, Samaneh; Poursadeghfard, Maryam; Beladimoghadam, Nahid; Razazian, Nazanin; Ayoubi, Saeideh; Rezaeimanesh, Nasim; Eskandarieh, Sharareh; Moghadasi, Abdorreza Naser title: Characteristics of COVID-19 in patients with multiple sclerosis date: 2021-11-30 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2021.103437 sha: 358c80dea7f529bda1c85028243700a6563fe770 doc_id: 758801 cord_uid: cx0ru57f BACKGROUND: : Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population. METHODS: : Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe. RESULTS: : A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003- 5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41- 6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms. CONCLUSION: : The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity. Multiple sclerosis (MS) with an age-adjusted prevalence of 137.6 and incidence of 6.7 per 100000 is a common neurologic disease in Iran (Almasi-Hashiani et al., 2020; Hosseinzadeh et al., 2019) . A recent systematic review showed high and rising prevalence in the country (Azami et al., 2019) . Apart from high rates of depression, studies have shown patients' concerns about the effect of the recent pandemic on their disease and treatment (Ramezani et al., 2021; Rezaeimanesh et al., 2020; Zhang et al., 2021) . Worried about becoming infected, many patients have postponed their usual medical care (Zhang et al., 2021) . It was found that many Iranian MS patients were not informed about necessary changes in treatment protocols in case of infection with SARS-CoV2 (Ghajarzadeh et al., 2021) . More clarification of the situation would help manage the distress. There are epidemiologic studies of COVID-19 on MS patients. A large cohort, of 42899 MS cases, from the US reported the same infection rate in MS population relative to the general US population (Kovvuru et al., 2021) . A unicentric study in Iran also showed the same incidence of COVID-19 in MS patients compared with the general Iranian population, but a higher risk of hospitalization in these patients . However, there are other reports with various, sometime contradicting, results (Sharifian-Dorche et al., 2021) . As far as the authors are concerned, this study is the first multicenter report of COVID-19 on Iranian patients with MS, which attempted to address the disease characteristics, risk factors of severity, and differences with the general population. 2.1. Setting: The nationwide MS registry of Iran (NMSRI) was established in 2018. The validity and reliability of the MS questionnaire had been previously confirmed (Shahin et al., 2019) . The study was carried out between July 2020 and March 2021. Several workshops were held to educate admins in nine provinces of Iran: East Azerbaijan, Fars, Guilan, Isfahan, Kermanshah, Khuzestan, Mazandaran, Qazvin, and Tehran. Admins had to enter the data from day clinics, private and public hospitals, and private offices. MS was diagnosed based on Mc Donald's criteria 2017 by neurologists (Carroll, 2018) . infection was confirmed by an internist or infectious diseases specialist with reviewing clinical aspects, polymerase chain reaction (PCR), and/or lung CT scan. MS patients with COVID-19 were entered into the registry. Identification data, demographic characteristics (age, gender, and place of residence), and information on MS and COVID-19 were collected. Patients were categorized into the two groups of older or younger than 50 years old. MS data included: type (clinically isolated syndrome (CIS), relapsing-remitting (RR), secondary progressive (SP), primary progressive (PP)), expanded disability scoring scale (EDSS), diseasemodifying drug (DMD), and whether the patient had received steroid in the last three months. MS types were grouped as progressive versus non-progressive forms. Patients were also categorized to cases with EDSS lower or higher than three. As there were data on the effect of antiCD20s on the course of COIVD-19, they were analyzed compared to other treatment choices, separately. Information on COVID-19 characteristics included: symptoms, PCR and CT results, drugs, and admission information. The symptoms of COVID-19 were categorized into more severe ones (dyspnea, altered mental status, or those symptoms resulting in hospital admission) and less severe symptoms (others). This categorization was based on the results of studies evaluating symptoms and prognosis (Tenforde et al., 2020) (Attia et al., 2021) , and also the protocols in clinical management of Iranian COVID patients. Admins were responsible to check for errors in data entry and solve any problem during follow ups. Finally, files with incomplete key information were excluded. Duplication was checked by national code number. To ensure the privacy of the patients, limited access to the registry was defined for each registrar. Study details, and goals were explained to the patients. Enrollment was optional. The project protocol has been approved by ethical committee of Tehran University of Medical Sciences (IR.TUMS.NI.REC.1400.030). Q-Q plots and Kolmogorov-Smirnov (K-S) tests were run to check for normality. Descriptive analysis included frequency for qualitative variables, mean ± standard deviation (SD) for quantitative variables, and median (interquartile range (IQR)) for categorical ones like EDSS. Univariate analysis was applied to find factors with significant association with the outcome measures (p value < 0.2). After entering the found factors to the final multivariate regression models, those with p value < 0.05 were considered significant. IBM® SPSS® version 26 was used. During the study period, 397 eligible patients were identified and none was excluded. The basic characteristics of the patients are summarized in Table 1 . (27) 74 (19) 40 (10) 38 (10) 35 (9) 34 (9) 33 (8) 27 (7) 8 ( (85) 111 (28) 71 (18) 8 (2) Table 2 . (60) 232 (58) 217 (55) 200 (50) 187 (47) 161 (41) 155 (39) 123 (31) 55 (14) 49 (12) 12 ( This is the first multicentric report on Iranian MS patients infected with COVID-19 from NMSRI. The majority were female patients, in their mid-thirties, with RR type of MS, and in the earlier stages of the disease. Most of the patients took vitamin D as a supplement. Body pains, malaise, and fever were the most common complaints. The death rate from COVID-19 approximated those of previous reports from Iran and other countries Sormani et al., 2021a) . It is obviously lower than the overall death rate from the pandemic in Iran (3%), officially announced by the ministry of health https://www.worldometers.info/coronavirus/country/iran/. The admission rate was lower compared to the previous unicentric Iranian study (18% in our study versus 25%) . The risk of infection with SARS-CoV2 and its severe course in MS patients was not higher compared to general population in other cohorts, either (Moreno-Torres et al., 2021; Stastna et al., 2021) . However, the data from the United States is in a different direction (Salter et al., 2021b; Sormani et al., 2021b) . No exact data on the rate of ICU admission was available in our registry. About the relation between MS and COVID-19, there are notable debates. Our study revealed the association of anti CD20s with more severe forms of COVID-19 including severe symptoms like altered mental status or dyspnea, and more hospitalization rates. This is in line with some of the previous studies (Luna et al., 2020; Safavi et al., 2020; Sharifian-Dorche et al., 2021; Sormani et al., 2021a) . The proposed mechanism is the manipulation of the immune system with depleting B-cell lineage. Nevertheless, some scholars argue for the role of B-cells in the antiviral immune response (Giovannoni, 2020; Montero-Escribano et al., 2020) . Some even suggest that reduced B-cell-related cytokine responses (e.g., interleukin 6) may play a favorable role in limiting the inflammatory phase of COVID-19 (Novi et al., 2020) . The obvious point is the need for further research on the subject. There is data on neurologists' attitude towards treatment changes during the pandemic (Mateen et al., 2020) . In spite of the concerns, a minor change in the treatment protocols was reported in our database. Regarding other aspects of MS disease, Louapre et al. demonstrated age, EDSS, and obesity as independent risk factors for COVID-19 severity in MS patients (Louapre et al., 2020) . In another study in New York, age, presence of comorbidities, progressive disease, and a nonambulatory status were found to be related to more severe diseases (Parrotta et al., 2020) . Also, a recently published study showed increased disability, older age, black race, cardiovascular comorbidities, and recent treatment with corticosteroids could be associated with more clinical severity (Salter et al., 2021a) . The association of steroids and anti CD20s with severe course is found in some other studies, as well (Sormani et al., 2021b; Stastna et al., 2021) . Our findings agree in some aspects with previously mentioned studies whereas a strong association with DMT type was found. No association was found between baseline use of supplements (e.g., vitamin D) and COVID-19 severity. Nevertheless, as some studies seem to contradict these results (Lordan et al., 2021; Pinnawala et al., 2021) , more investigations are required in the future. Apart from low dose steroids (2021), most drugs listed here as COVID drugs are proven to be ineffective (Sanders et al., 2020; Tang et al., 2020) , https://www.covid19treatmentguidelines.nih.gov/outpatientmanagement/, however as the data was gathered over the last year, they were included in the study. Our data confirmed many of the previous mentioned results (Sanders et al., 2020; Tang et al., 2020) . As growing evidence shows, chronic diseases like diabetes mellitus and hypertension may alter the prognosis in COVID-19 patients (Abu-Farha et al., 2020; Alyammahi et al., 2021) . Lack of such correlation in our study (except for asthma that is predictable to cause more dyspnea) may be due to the younger age of our study population and the low prevalence of such diseases. Despite substantial studies about COVID-19 in MS patients, the discrepancy in the literature is still of note. There are even concerns about the long-term effects of COVID-19 on MS patients (Di Stadio et al., 2020) . Thereafter, more extensive data registries may be of help to depict a clearer viewpoint on the matter. Evidence of an increased prevalence of multiple sclerosis: a population-based study of Tehran registry during The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities Altered mental status is a predictor of poor outcomes in COVID-19 patients: A cohort study Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis McDonald MS diagnostic criteria: Evidence-based revisions Attitude and Knowledge of Patients with Multiple Sclerosis (MS) About COVID-19 as Provided by Physicians Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 Incidence of multiple sclerosis in Iran: a nationwide, population-based study Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Risk and outcomes of COVID-19 in patients with multiple sclerosis COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19 Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching COVID-19 and Its Effects on the MS Symptoms B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Multiple sclerosis national registry system in Iran: Validity and reliability of a minimum data set COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review Musc-19 Study, G., 2021a. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis Covisep study, g., 2021b. DMTs and Covid-19 severity Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia Characteristics of Adult Outpatients and Inpatients with COVID-19 -11 Academic Medical Centers Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: A cross-sectional study